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A bs tr ac t
Background
We aimed to assess the safety and efficacy of thrombectomy for the treatment of 
stroke in a trial embedded within a population-based stroke reperfusion registry.
Methods
During a 2-year period at four centers in Catalonia, Spain, we randomly assigned 
206 patients who could be treated within 8 hours after the onset of symptoms of 
acute ischemic stroke to receive either medical therapy (including intravenous al-
teplase when eligible) and endovascular therapy with the Solitaire stent retriever 
(thrombectomy group) or medical therapy alone (control group). All patients had 
confirmed proximal anterior circulation occlusion and the absence of a large in-
farct on neuroimaging. In all study patients, the use of alteplase either did not 
achieve revascularization or was contraindicated. The primary outcome was the 
severity of global disability at 90 days, as measured on the modified Rankin scale 
(ranging from 0 [no symptoms] to 6 [death]). Although the maximum planned 
sample size was 690, enrollment was halted early because of loss of equipoise after 
positive results for thrombectomy were reported from other similar trials.
Results
Thrombectomy reduced the severity of disability over the range of the modified 
Rankin scale (adjusted odds ratio for improvement of 1 point, 1.7; 95% confidence 
interval [CI], 1.05 to 2.8) and led to higher rates of functional independence (a score 
of 0 to 2) at 90 days (43.7% vs. 28.2%; adjusted odds ratio, 2.1; 95% CI, 1.1 to 4.0). 
At 90 days, the rates of symptomatic intracranial hemorrhage were 1.9% in both the 
thrombectomy group and the control group (P = 1.00), and rates of death were 
18.4% and 15.5%, respectively (P = 0.60). Registry data indicated that only eight pa-
tients who met the eligibility criteria were treated outside the trial at participating 
hospitals.
Conclusions
Among patients with anterior circulation stroke who could be treated within 8 hours 
after symptom onset, stent retriever thrombectomy reduced the severity of post-
stroke disability and increased the rate of functional independence. (Funded by 
Fundació Ictus Malaltia Vascular through an unrestricted grant from Covidien and 
others; REVASCAT ClinicalTrials.gov number, NCT01692379.)
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Recently completed prospective, randomized trials involving patients with acute stroke have consistently shown a 
clinical benefit for mechanical thrombectomy.1-4 
Our study, called the Randomized Trial of Revas-
cularization with Solitaire FR Device versus Best 
Medical Therapy in the Treatment of Acute Stroke 
Due to Anterior Circulation Large Vessel Occlu-
sion Presenting within Eight Hours of Symptom 
Onset (REVASCAT), shares the following four 
features with the previously cited trials: enroll-
ment limited to patients with imaging-based evi-
dence of proximal occlusion of the M1 segment 
(main trunk) of the middle cerebral artery with 
or without concomitant occlusion of the internal 
carotid artery, imaging-based exclusion of pa-
tients with a large core (indicating large cerebral 
infarct), use of a stent retriever, and ongoing qual-
ity-improvement efforts to reduce the time to re-
perfusion to the minimum.
The lack of consecutive enrollment has been 
identified as a major shortcoming in endovascu-
lar stroke trials.5 To account for this potential 
limitation by determining the extent of consecu-
tive enrollment, the study was conducted within 
Sistema Online d’Informació de l’Ictus Agut de 
Catalunya (SONIIA), a concomitant, population-
based registry of acute stroke reperfusion proce-
dures6 that captured patients within the same 
catchment area as that of the participating hos-
pitals in our study, including patients who were 
treated in the thrombectomy group.
The aim of this study was to determine the 
efficacy and safety of neurovascular thrombec-
tomy with the Solitaire stent retriever in con-
junction with medical therapy versus medical 
therapy alone, among eligible patients with 
acute ischemic stroke that could be treated 
within 8 hours after the onset of symptoms and 
to assess the proportion of eligible patients who 
were treated outside the study.
Me thods
Study Design and Oversight
REVASCAT was a multicenter, prospective, ran-
domized, sequential, open-label phase 3 study 
with blinded evaluation. We compared throm-
bectomy with medical therapy alone in eligible 
patients who had received intravenous alteplase 
within 4.5 hours after the onset of symptoms 
without revascularization after 30 minutes of al-
teplase infusion or who had a contraindication to 
intravenous alteplase. The trial was monitored by 
an independent data and safety monitoring board.
The steering committee designed the study, 
had unrestricted access to the data, and together 
with all other coauthors reviewed the analysis 
with study statisticians, wrote the first and sub-
sequent drafts of the manuscript, and attest to 
the integrity of the trial, the fidelity of this re-
port to the study protocol, and the completeness 
and accuracy of the reported data. The study was 
funded by an unrestricted grant from the manu-
facturer of the stent retriever (Covidien), which 
was not involved in the design or conduct of the 
study or in the writing of the protocol or the 
manuscript.
The study protocol,7 which is available with 
the full text of this article at NEJM.org, was ap-
proved by a central medical ethics committee and 
by the research board at each participating center. 
All patients or their surrogates provided written 
informed consent.
Patients
From November 2012 through December 2014, 
we screened patients at four study centers in Cat-
alonia, Spain. Eligible patients were between the 
ages of 18 and 80 years, had an occlusion in the 
proximal anterior circulation that could be treat-
ed within 8 hours after symptom onset, had a 
prestroke functional ability of 1 or less on the 
modified Rankin scale (ranging from 0 [no symp-
toms] to 6 [death]), and had a baseline score of at 
least 6 points on the National Institutes of Health 
Stroke Scale (NIHSS), which ranges from 0 to 42, 
with higher values indicating more severe deficit. 
The main exclusion criteria on imaging were evi-
dence of a large ischemic core, as indicated by an 
Alberta Stroke Program Early Computed Tomog-
raphy Score (ASPECTS) of less than 7 on com-
puted tomography (CT) without the use of con-
trast material or a score of less than 6 on 
diffusion-weighted magnetic resonance imaging 
(MRI). (ASPECTS values range from 0 to 10, with 
higher values indicating less infarct burden.) Ad-
ditional details with respect to imaging require-
ments, interventions, and clinical and radiologic 
assessments are provided in the Supplementary 
Appendix, available at NEJM.org.
After the enrollment of 160 patients, the in-
clusion criteria were modified to include pa-
tients up to the age of 85 years with an ASPECTS 
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score of more than 8. Detailed clinical and im-
aging criteria for inclusion and exclusion are pro-
vided in Table S1 in the Supplementary Appendix.
Study Sites and Interventionists
Study sites consisted of certified comprehensive 
stroke centers that treat more than 500 patients 
with acute stroke and perform more than 60 me-
chanical stroke thrombectomy procedures annu-
ally and are staffed by trained neurointervention-
alists who are required to have performed at least 
20 thrombectomies with the Solitaire device. 
Participating sites were the four large, designat-
ed, comprehensive stroke centers in Catalonia, 
Spain, covering a defined population of 7.5 mil-
lion. The Catalan Health Authorities monitored 
adherence to the medical-therapy guidelines at 
the sites (see the Methods section in the Supple-
mentary Appendix).
Comprehensive Registry
During the trial, all reperfusion treatments (en-
dovascular or intravenous) for acute stroke in 
Catalonia were captured through SONIIA, a pro-
spective, population-based, and externally moni-
tored registry regulated by the Catalan Department 
of Health. (Details regarding the SONIIA registry 
are provided in the Supplementary Appendix.)
Randomization
We randomly assigned 206 patients in a 1:1 ratio 
to receive either medical therapy (including intra-
venous alteplase when eligible) and endovascular 
treatment with the Solitaire stent retriever 
(thrombectomy group) or medical therapy alone 
(control group). We used a real-time computer-
ized randomization procedure that was stratified 
according to age (≤70 or >70 years), baseline NIHSS 
score (6 to 16 or ≥17), therapeutic window (≤4.5 
or >4.5 hours), occlusion site (intracranial inter-
nal carotid artery or M1 segment [main trunk of 
the middle cerebral artery]), and participating 
center.
Primary Outcome
The primary outcome was the severity of disabil-
ity at 90 days, according to the distribution of 
scores on the modified Rankin scale.8 Severe dis-
ability (score of 5) and death (score of 6) were 
combined into a single, worst category.1,2,9 Local 
and external certified assessors who were un-
aware of study-group assignments separately 
evaluated the primary outcome variable in each 
patient by means of a structured interview.10 The 
primary analysis was based on central evaluation 
by means of video recording (in 106 evaluations). 
In cases in which the video recording was un-
available, outcomes as determined in person by 
local investigators in a blinded manner were 
used as default (in 65 evaluations). Sensitivity 
analyses were performed with outcome determi-
nations in a blinded manner by local investiga-
tors and central readers. Decisions regarding the 
adjudication method for the primary outcome 
were made by the steering committee in a blind-
ed manner before the first interim analysis. (Ad-
ditional details are provided in the Methods sec-
tion in the Supplementary Appendix.)
Secondary and Safety Outcomes
Secondary outcomes included centrally adjudi-
cated infarct volumes on CT or MRI at 24 hours, 
vessel revascularization on CT angiography (CTA) 
or MR angiography (MRA) at 24 hours (data not 
yet analyzed), early dramatic response to treat-
ment (defined as a decrease in the NIHSS score 
of ≥8 from baseline or an NIHSS score of 0 to 2 at 
24 hours), the NIHSS score and Barthel Index 
(with the latter on a scale from 0 to 100, with 
higher scores indicating less disability) at 90 days, 
and health status, as measured on the EuroQol 
Group 5-Dimension Self-Report Questionnaire 
(EQ-5D, on a scale of −0.33 to 1, with higher val-
ues indicating a better quality of life) at 90 days. In 
the thrombectomy group, the core laboratory 
used post-procedure conventional angiography 
to adjudicate successful vessel revascularization, 
which was defined as a grade of 2b or 3 (indicat-
ing reperfusion of more than 50% of the affected 
territory) on the modified Thrombolysis in Cere-
bral Infarction (mTICI) scale of 0 to 3, with high-
er grades indicating increased reperfusion.
Safety outcomes were the rates of death and 
symptomatic intracranial hemorrhage at 90 days, 
as confirmed on neuroimaging (CT or MRI) evalu-
ated by the core laboratory, primarily according 
to the definition used in the Safe Implementation 
of Thrombolysis in Stroke–Monitoring Study 
(SITS-MOST),11 which was parenchymal hemor-
rhage type 2 on follow-up imaging and neuro-
logic deterioration of at least 4 points on the 
NIHSS. Evaluators also used the definition of 
symptomatic intracranial hemorrhage that was 
used in the second European–Australasian Acute 
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Stroke Study (ECASS II)12 — namely, any type of 
intracerebral hemorrhage on post-treatment im-
aging with an increase of at least 4 points on the 
NIHSS. An independent clinical events commit-
tee adjudicated safety outcomes, procedure-relat-
ed complications (e.g., arterial perforation, arte-
rial dissection, and embolization in a previously 
uninvolved vascular territory), and serious adverse 
events.
Statistical Analysis
All analyses were performed in the intention-to-
treat population. The measure of effect size was 
a cumulative odds ratio as calculated by logistic 
regression (shift analysis). This analysis relies on 
the assumption of an odds ratio behind any cut-
off point, which has been shown to be robust to 
minor deviations.8 The primary analysis has been 
adjusted both for minimization factors and for 
the intravenous use of alteplase. We calculated 
that the enrollment of 690 patients would pro-
vide a power of 90% to detect a difference in the 
distribution of scores on the modified Rankin 
scale with a one-sided significance level of 0.025 
in the analysis of the primary outcome, assum-
ing an expected result of an odds ratio of 1.615.
Because of the uncertainty about the size of the 
treatment effect for the primary outcome, 
REVASCAT was designed as a sequential study. 
On the basis of stopping boundaries for the 
Whitehead triangular test, we planned to con-
duct a maximum of four equally spaced reviews 
when enrollment had reached approximately 
25%, 50%, 75%, and 100% of the sample size. 
We assigned lower individual limits of signifi-
cance to the four analyses in order to achieve an 
overall shared one-sided alpha level of 0.025.
Trial Termination
The first interim analysis was performed as 
planned after 25% patients (174 of the maximum 
sample size) had completed 90 days of follow-up. 
The steering committee accepted the recommen-
dation of the data and safety monitoring board 
to stop recruitment because of loss of equipoise 
(as described in detail in the Supplementary Ap-
pendix). Although the interim results did not 
reach the prespecified stopping boundaries (see 
the results of the first interim analysis in Fig. 
S6-1 in the Supplementary Appendix), study re-
cruitment was terminated because of emerging 
results from three other studies2-4 that showed 
the efficacy of thrombectomy, which raised ethi-
cal concerns about further assignment of pa-
tients to the control group. Since the trial was 
stopped because the primary hypothesis was no 
longer an open question, we changed our goal 
from hypothesis testing to estimation. Since just 
one analysis was performed, adjustment for mul-
tiple comparisons was no longer required, and 
95% confidence intervals are reported (details 
are provided in the Supplementary Appendix). All 
reported 95% confidence intervals and P values 
are nominal and based on the recorded data.
R esult s
Patients
A total of 206 patients were enrolled in the study 
(Fig. S1 in the Supplementary Appendix). One pa-
tient withdrew consent immediately after ran-
domization and was not included in the analysis. 
No crossovers occurred. All patients had an 
available evaluation at 90 days for the primary 
outcome. In 5 patients with a score of 4 or 5 on 
the modified Rankin scale, the video evaluation 
was replaced by a telephone interview. The inten-
tion-to-treat analysis included 103 patients in the 
thrombectomy group and 103 in the control 
group.
During the study period, 2576 patients with 
ischemic stroke were included in the SONIIA 
registry, making up 15.6% of all admissions for 
ischemic stroke in Catalonia and resulting in an 
aggregate reperfusion-therapy rate of 17 per 
100,000 residents of Catalonia per year. Intrave-
nous thrombolysis alone was used in 2036 pa-
tients (79%). The remaining 540 patients (21%) 
underwent endovascular therapy, including 260 
who underwent a combination of intravenous 
alteplase and thrombectomy (Fig. S2 and S3 in the 
Supplementary Appendix). Of the 540 patients 
who underwent thrombectomy, 464 (86%) were 
treated at hospitals included in our study.
Periodic review of registry data and evalua-
tion of medical records at local sites that was 
intended to confirm eligibility revealed that 111 
of 464 patients receiving endovascular therapy 
met the study criteria; of these patients, 103 were 
treated in our study. Therefore, only 8 patients 
who were eligible to participate in our study re-
ceived endovascular therapy outside the trial at 
participating hospitals (Table S3 and Fig. S3 in 
the Supplementary Appendix).
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Table 1. Characteristics of the Patients and Workflow Measures at Baseline.*
Variable
Thrombectomy
(N = 103)
Control
(N = 103)
Mean age ±SD — yr 65.7±11.3 67.2±9.5
Male sex — no. (%) 55 (53.4) 54 (52.4)
Medical history — no. (%)
Atrial fibrillation 35 (34.0) 37 (35.9)
Diabetes mellitus 22 (21.4) 19 (18.4)
Hypertension 62 (60.2) 72 (69.9)
Ischemic stroke or transient ischemic attack 12 (11.7) 18 (17.5)
No symptoms on modified Rankin scale before stroke — no. (%) 86 (83.5) 83 (80.6)
NIHSS score†
Median (IQR) 17.0 (14.0–20.0) 17.0 (12.0–19.0)
6–16 — no. (%) 46 (44.7) 45 (43.7)
17 or more — no. (%) 57 (55.3) 58 (56.3)
Median systolic blood pressure at hospital arrival (IQR) — mm Hg 142 (128–155) 144 (124–157)
Median glucose level at hospital arrival (IQR) — mmol/liter 6.8 (5.9–7.9) 6.9 (6.2–8.0)
Treatment with intravenous alteplase — no. (%)‡ 70 (68.0) 80 (77.7)
Imaging characteristics
Median ASPECTS value (IQR)§ 7.0 (6.0–9.0) 8.0 (6.0–9.0)
Location of intracranial occlusion on CTA or MRA — no./total no. (%)¶
Intracranial internal carotid artery without involvement of M1 0 1/101 (1.0)
Terminal internal carotid artery with involvement of M1 26/102 (25.5) 27/101 (26.7)
M1 66/102 (64.7) 65/101 (64.4)
Single M2 10/102 (9.8) 8/101 (7.9)
Ipsilateral cervical carotid occlusion — no. (%)‖ 19/102 (18.6) 13/101 (12.9)
Workflow times
Median time from stroke onset to intravenous alteplase (IQR) — min 117.5 (90.0–150.0) 105.0 (86.0–137.5)
Median time time from stroke onset to imaging (IQR) — min** 192 (129–272) 183 (132–263)
Median time from stroke onset to randomization (IQR) — min 223 (170–312) 226 (168–308)
Under 3 hr — no. (%) 32 (31.1) 31 (30.1)
3–5.9 hr — no. (%) 58 (56.3) 65 (63.1)
6–8 hr — no. (%) 13 (12.6) 7 (6.8)
Median time from stroke onset to groin puncture (IQR) — min 269 (201–340) NA
Median time from stroke onset to revascularization (IQR) — min 355 (269–430) NA
* There were no significant differences between the two groups. To convert the values for glucose to milligrams per 
deciliter, divide by 0.05551. CTA denotes computed tomography angiography, IQR interquartile range, M1 main trunk 
of the middle cerebral artery, M2 first-order branch of the main trunk of the middle cerebral artery, MRA magnetic 
resonance angiography, and NA not applicable.
† Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating 
more severe neurologic deficits.
‡  Intravenous alteplase was administered before randomization, except in one patient, and at least 30 minutes before 
confirmation of the target artery occlusion on CTA or MRA. Contraindications for intravenous alteplase according to 
group are provided in Table S4 in the Supplementary Appendix.
§ The Alberta Stroke Program Early Computed Tomography Score (ASPECTS) is an imaging measure of the extent of 
ischemic stroke. Scores range from 0 to 10, with higher scores indicating a smaller infarct core. Listed are values for 
the core laboratory assessment.
¶ The location of the occlusion was not available in 1 patient in the intervention group and 2 patients in the control 
group.
‖ Ipsilateral carotid stenting was performed in nine patients (8.7%) in the thrombectomy group.
** The listed time corresponds to the imaging performed before randomization at least 30 minutes after the initiation of 
intravenous alteplase (in patients in whom the drug was administered).
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Table 2. Primary and Secondary Clinical and Imaging Outcomes.*
Outcome
Thrombectomy
(N = 103)
Control
(N = 103)
Effect
Variable
Unadjusted 
Value
(95% CI)
Adjusted  
Value
(95% CI)
Primary outcome: score on modified Rankin 
scale at 90 days
NA NA Common 
odds ratio
1.7 (1.04 to 2.7) 1.7 (1.05 to 2.8)
Secondary outcome
Score of 0 to 2 on modified Rankin scale 
at 90 days — no. (%)†
45 (43.7) 29 (28.2) Odds ratio 2.0 (1.1 to 3.5) 2.1 (1.1 to 4.0)
Dramatic neurologic improvement at 24 h 
— no./total no. (%)‡
59/100 (59.0) 20/100 (20.0) Odds ratio 5.5 (2.9 to 10.3) 5.8 (3.0 to 11.1)
Median NIHSS score at 90 days (IQR) 2.0 (0.0 to 8.0) 6.0 (2.0 to 11.0) Beta −2.7 (−4.4 to −0.9) −2.4 (−4.1 to −0.8)
Barthel Index score of 95 to 100 at 90 days 
— no./total no. (%)§
47/82 (57.3) 23/87 (26.4) Odds ratio 3.7 (2.0 to 7.1) 4.2 (2.1 to 8.4)
Median EQ-5D score at 90 days (IQR) ¶ 0.65 (0.21 to 0.79) 0.32 (0.13 to 0.70) Beta 0.13 (0.03 to 0.23) 0.11 (0.02 to 0.21)
Infarct volume at 24 hr
Patients evaluated on CT:diffusion-
weighted MRI — no.
91:10 98:5
Median (IQR) — ml 16.3 (8.3 to 58.5) 38.6 (11.9 to 86.8) P value‖ P = 0.02
* CT denotes computed tomography, and MRI magnetic resonance imaging.
† The modified Rankin scale of functional disability ranges from 0 (no symptoms) to 6 (death).
‡ Dramatic neurologic improvement was defined as a reduction of at least 8 points on the NIHSS or a score of 0 to 2 at 24 hours. NIHSS 
scores at 24 hours were not available for 3 patients in each group because of early death or intubation.
§ Scores on the Barthel Index range from 0 to 100, with higher values indicating good performance of daily living activities. A score between 
95 and 100 indicates no disability that interferes with daily activities. Included are patients who were alive at 90 days.
¶ Scores on the EuroQoL Group 5-Dimension Self-Report Questionnaire (EQ-5D) range from −0.33 to 1, with higher scores indicating a better 
quality of life.
‖ The P value was calculated by means of the Wilcoxon rank-sum test.
Baseline Characteristics
Baseline characteristics were similar in the two 
study groups (Table 1, and Table S4 in the Sup-
plementary Appendix). The median NIHSS score 
was 17, the median ASPECTS score was 7 in the 
thrombectomy group and 8 in the control group, 
and intravenous alteplase was administered to 
68.0% of patients in the thrombectomy group 
and 77.7% of those in the control group. The me-
dian time from stroke onset to randomization 
was 225 minutes.
Intervention Details
Thrombectomy was performed in 98 of 103 pa-
tients in the thrombectomy group. Ipsilateral ca-
rotid stenting was performed in 9 patients. Seven 
procedures in the thrombectomy group (6.7%) were 
performed under general anesthesia. Outside of 
protocol, 1 patient was treated with intracranial 
angioplasty after failed attempts with the stent 
retriever, and 1 patient received intraarterial al-
teplase. Workflow metrics and procedural char-
acteristics are provided in Table 1, and Table S5 
in the Supplementary Appendix.
Primary Outcome
The primary outcome analysis showed a common 
odds ratio of improvement in the distribution of the 
modified Rankin scale score of 1.7 (95% confi-
dence interval [CI], 1.05 to 2.8) favoring thrombec-
tomy (Table 2 and Fig. 1). The absolute between-
group difference in the proportion of patients who 
were functionally independent (score of 0 to 2 on 
the modified Rankin scale) was 15.5 percentage 
points, favoring thrombectomy (43.7% vs. 28.2%; 
adjusted odds ratio, 2.1; 95% CI, 1.1 to 4.0) (Table 2).
Secondary Outcomes
Secondary outcomes also favored the thrombec-
tomy group (Table 2). Successful revasculariza-
tion was achieved in 66% of patients in the 
thrombectomy group according to core labora-
tory assessments (Table 3) and in 80% of the 
patients according to the assessments of local 
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interventionalists. (For details, see Table S5 in 
the Supplementary Appendix.)
Safety Variables
There were no significant between-group differ-
ences between the thrombectomy group and the 
control group in the rates of death (18.4% vs. 
15.5%, P = 0.60) or symptomatic intracranial hem-
orrhage (1.9% in each group, P = 1.00) at 90 days. 
Rates of other serious adverse events during the 
90-day follow-up period were also similar in the 
two study groups (Table 4). A complete list of ad-
verse events is provided in Tables S6 and S7 in the 
Supplementary Appendix.
Subgroup Analyses
We did not detect significant differences in the 
effect of thrombectomy in prespecified subgroup 
analyses. However, the relatively small sample size 
resulting from the early termination of the trial 
reduced the power of these planned analyses (Fig. 
2, and Fig. S5 in the Supplementary Appendix).
Sensitivity Analyses
The primary outcome analysis that was based 
only on the local evaluator’s adjudication in a 
blinded manner showed higher treatment effects 
for thrombectomy (odds ratio, 1.9; 95% CI, 1.1 to 
3.2) than the above-mentioned odds ratios. De-
tails regarding the sensitivity analyses are provid-
ed in Figure S6 in the Supplementary Appendix.
Discussion
Our study findings are consistent with those of 
recently reported trials1-4 showing that in pa-
tients with acute stroke caused by a proximal 
large-vessel occlusion and an absence of a large 
infarct on baseline imaging, mechanical throm-
bectomy with the Solitaire stent retriever was 
safe and led to improved clinical outcomes, as 
compared with medical therapy alone. Rates of 
functional independence were increased by 15.5 
percentage points in the thrombectomy group, 
which means that 6.5 patients would need to be 
treated with thrombectomy to prevent one case 
of functional dependency or death. Thrombec-
tomy was associated with a shift toward better 
outcomes across the entire spectrum of disability.
There are important features that distinguish 
our study from other similar trials.1-4,13 Our 
study was embedded into a concomitant reperfu-
sion registry that captured all endovascular stroke 
treatments that were performed in the target 
population during the study. As such, we had 
access to data regarding the number of poten-
tially eligible patients who were treated outside 
the study at participating centers and over the 
entire target population. The vast majority of 
patients who were treated with endovascular 
therapy and who met the eligibility criteria for 
our study were treated within our study.
We aimed to avoid inclusion of patients who 
had an early response to intravenous alteplase. A 
prerequisite for enrollment was imaging proof of 
the presence of a qualifying occlusion 30 min-
utes after the administration of alteplase, a fac-
tor that partially explains the longer times from 
hospital arrival to reperfusion and the lower 
rates of mTICI scores of 2b or 3 in our study, as 
compared with values in the Solitaire with the 
Intention for Thrombectomy as Primary Endo-
vascular Treatment (SWIFT PRIME) study,1 the 
Endovascular Treatment for Small Core and 
Anterior Circulation Proximal Occlusion with 
Emphasis on Minimizing CT to Recanalization 
Times (ESCAPE) study,2 and the Extending the 
Time for Thrombolysis in Emergency Neurologi-
cal Deficits–Intra-arterial (EXTEND-IA) study.3 
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Figure 1. Distribution of Functional Scores at 90 Days (Intention-to-Treat 
Population).
Shown are scores on the modified Rankin scale for patients in the throm-
bectomy group and the control group who were evaluated by means of 
video recording (in 106 patients) and by local investigators (in 65 pa-
tients). Scores on the modified Rankin scale range from 0 to 6, with 0 indi-
cating no symptoms; 1, no clinically significant disability; 2, slight disability 
(able to handle own affairs without assistance but unable to carry out all 
previous activities); 3, moderate disability requiring some help, but able to 
walk unassisted; 4, moderately severe disability (unable to attend body 
needs and unable to walk); 5, severe disability (requiring constant nursing 
care and attention); and 6, death. Scores of 5 and 6 were combined for the 
analysis. A significant difference between the thrombectomy group and 
the control group was noted in the overall distribution of scores (adjusted 
common odds ratio for improvement of 1 point on the modified Rankin 
scale, 1.7; 95% confidence interval, 1.05 to 2.8).
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Table 3. Scores on the Modified Thrombolysis in Cerebral Infarction Scale for 102 Patients in the Thrombectomy 
Group.*
Score At Baseline After Treatment
no. of patients (%)
0: No reperfusion 84 (82.4) 8 (7.8)
1: Antegrade flow past the initial occlusion but limited distal branch filling 
with little or slow distal reperfusion
10 (9.8) 2 (2.0)
2a: Antegrade reperfusion of less than 50% of the previously ischemic territory 4 (3.9) 25 (24.5)
2b: Antegrade reperfusion of more than 50% of the previously ischemic  
territory
1 (1.0) 48 (47.1)
3: Complete antegrade reperfusion of the previously ischemic territory, with  
absence of visualized occlusion in all distal branches
2 (2.0) 19 (18.6)
Could not be assessed 1 (1.0) 0
* P<0.001 for the overall comparison between baseline values and values after treatment by McNemar’s test for trend. 
Listed are data obtained on angiography during the core laboratory evaluation. Data were missing for one patient.
Given the rigorous vetting process for interven-
tionists that was applied in our study, it is un-
likely that the observed differences in reperfu-
sion rates were due to potential differences in 
operator skill. It is more likely that these differ-
ences were due to the fact that the time from 
symptom onset to randomization was longer in 
our study and inclusion criteria resulted in a 
study population enriched with patients in whom 
occlusive lesions had a reduced response to 
thrombectomy attempts, similar to the patients 
enrolled in the Multicenter Randomized Clinical 
Trial of Endovascular Treatment for Acute Ischemic 
Stroke in the Netherlands (MR CLEAN).4
In our study, imaging that was used for the 
selection of patients was performed in the ma-
jority of cases with widely available methods (CT 
and CTA) and aimed to confirm large-vessel oc-
clusion while excluding patients with large-
ischemic core. Similar to findings in other stud-
ies, we observed discrepancies between central 
and investigator-adjudicated ASPECTS scores 
and occlusion sites.1,2 Centrally adjudicated im-
aging studies showed that 25% of the patients 
had ASPECTS scores of 6 or less and 9% had 
occlusions in the M2 segment (first-order branch 
of the main trunk of the middle cerebral artery), 
which constituted an exclusion criteria. If enroll-
ment had been carried out on the basis of cen-
trally adjudicated requirements for imaging, a 
significant proportion of patients who were en-
rolled in our study might have been excluded, 
which highlights some of the challenges associ-
ated with conducting imaging-based endovascu-
lar stroke trials. It can be argued, however, that 
inclusion according to investigator-based inter-
pretation of imaging is a more accurate reflec-
tion of real-world clinical practice.
Because ASPECTS interpretation is less accu-
rate in estimating the core volume than are 
other imaging methods,14 our imaging-selection 
requirements may have allowed the inclusion of 
patients with infarct sizes that were larger than 
those in patients included in other trials.1-3 This 
factor, in conjunction with longer times from 
symptom onset to reperfusion, centrally adjudi-
cated outcomes, and imbalances in the proportion 
of patients with extracranial occlusion of the 
internal carotid artery, may explain the lower 
treatment effect seen in our study than in the 
SWIFT PRIME, ESCAPE, and EXTEND IA stud-
ies. The magnitude of benefit that we saw in our 
study was similar to that observed in MR CLEAN, 
with which our study shared many features.
Our sample size was not sufficient to permit 
robust assessments of the effects of thrombec-
tomy in the prespecified subgroups. However, 
similar to the findings of previous trials,1,2,4 the 
positive treatment effect in our study appeared 
to be generally consistent across nearly all pre-
specified subgroups, including those defined 
according to NIHSS score, vessel-occlusion site, 
baseline ASPECTS score, and administration of 
intravenous alteplase. The benefits appeared to 
be less consistent in subgroups that were de-
fined according to age and time window. Meta-
analyses of data from multiple trials15 will be 
required to clarify the benefits of thrombectomy 
in such subgroups.
In our study, thrombectomy with the Solitaire 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
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stent retriever was found to be safe. Although 
there were no between-group differences in the 
rates of symptomatic intracranial hemorrhage 
(as defined according to SITS-MOST criteria), 
the observed early nonsignificant increase in 
mortality in the thrombectomy group, as com-
pared with the control group, can be explained 
by multiple potential factors, including throm-
Table 4. Serious Adverse Events within 90 Days.*
Variable
Thrombectomy
(N = 103)
Control
(N = 103)
Between-Group Difference
(95% CI)
Risk Ratio
(95% CI)
no. (%)
Safety variable
Death
At 90 days 19 (18.4) 16 (15.5) −2.9 (−13.2 to 7.3) 1.2 (0.6 to 2.2)†
At ≤7 days 10 (9.7) 5 (4.9) −4.8 (−11.9 to 2.2) 2.0 (0.7 to 5.6)
Intracranial hemorrhage
Symptomatic‡
SITS-MOST criteria 2 (1.9) 2 (1.9) 0.0 (−3.8 to 3.8) 1.0 (0.1 to 7.0)
ECASS II criteria 5 (4.9) 2 (1.9) −2.9 (−7.8 to 2.0) 2.5 (0.5 to 12.6)
Asymptomatic§ 17 (16.5) 11 (10.7) −5.8 (−15.2 to 3.5) 1.5 (0.7 to 3.1)
Subarachnoid hemorrhage 5 (4.9) 2 (1.9) −2.9 (−7.8 to 2.0) 2.5 (0.5 to 12.6)
Parenchymal hematoma¶
Any 6 (5.8) 6 (5.8)
Type 1 3 (2.9) 4 (3.9)
Type 2 3 (2.9) 2 (1.9)
Other adjudicated serious adverse event
Neurologic worsening‖ 16 (15.5) 13 (12.6) −2.9 (−12.4 to 6.6) 1.2 (0.6 to 2.4)
Malignant cerebral edema** 11 (10.7) 10 (9.7) −1.0 (−9.2 to 7.3) 1.1 (0.5 to 2.5)
Recurrent stroke 4 (3.9) 3 (2.9) −1.0 (−5.9 to 4.0) 1.3 (0.3 to 5.8)
Procedure-related complication†† NA NA NA
Distal embolization in a different territory 5 (4.9)
Arterial dissection 4 (3.9)
Arterial perforation 5 (4.9)
Groin hematoma 11 (10.7)
Groin pseudoaneurysm 1 (1.0)
Vasospasm requiring treatment‡‡ 4 (3.9)
* Negative values for the between-group difference favor the control group. The risk ratio is for the thrombectomy group as compared with 
the control group. A complete list of adverse events is provided in Tables S6 and S7 in the Supplementary Appendix.
† The adjusted risk ratio for death at 90 days was 1.1 (95% CI, 0.8 to 1.4).
‡ Symptomatic intracranial hemorrhage was defined as parenchymal hemorrhage type 2 on follow-up imaging and neurologic deterioration 
of at least 4 points on the NIHSS, according to the Safe Implementation of Thrombolysis in Stroke–Monitoring Study (SITS-MOST) crite-
ria, or any symptomatic intracranial hemorrhage and neurologic worsening of at least 4 points on the NIHSS, according to the second 
European–Australasian Acute Stroke Study (ECASS II) criteria.
§ Asymptomatic intracranial hemorrhage was defined as any parenchymal hematoma with no neurologic worsening, as adjudicated by local 
investigators.
¶ Parenchymal hematomas were graded according to the neuroimaging core laboratory classification.
‖ Neurologic worsening was defined as an increase of at least 4 points on the NIHSS within 5 days after stroke onset that was not attributed to 
intracranial hemorrhage or malignant cerebral edema.
** Malignant cerebral edema was treated with decompressive hemicraniectomy in 3 patients in the thrombectomy group and in 6 patients in 
the control group.
†† All procedure-related complications were reported by the clinical events committee.
‡‡ Vasospasm events were reported by local investigators and the angiography core laboratory.
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1 2 4 6 8 10 12 14
Thrombectomy BetterControl Better
Age
<70 yr
≥70 yr
Baseline NIHSS
6–16
≥17
Site of occlusion
Intracranial ICA
M1
Both cervical ICA and TICA
or M1 occlusion
Time to randomization
≤4.5 hr
>4.5 hr
Alteplase
Yes
No
ASPECTS score
<8
≥8
No. of
Patients Odds Ratio (95% CI)Subgroup
2.2 (1.1–4.4)
1.4 (0.7–2.9)
1.4 (0.8–2.6)
2.7 (1.0–7.1)
1.8 (1.0–3.4)
 1.4 (0.6–3.3)
4.3 (1.5–12.5)
1.2 (0.7–2.2)
2.0 (1.0–4.0)
1.5 (0.7–3.1)
2.5 (1.3–4.6)
0
0.9 (0.4–2.0)
P Value for
Interaction
121
85
92
114
26
135
45
135
71
150
56
101
105
0.19
0.34
0.82
0.09
0.75
0.76
Figure 2. Subgroup Analyses.
The forest plot shows the effect size in the primary outcome variable (common odds ratio for improvement on the 
modified Rankin scale at 90 days, analyzed according to ordinal logistic regression and adjusted for minimization 
factors and the use of intravenous alteplase) across the prespecified subgroups and the Alberta Stroke Program 
Early Computed Tomography Score (ASPECTS). There were no significant differences between the thrombectomy 
group and the control group. The cutoff values and categories of the subgroups are those specified in the minimi-
zation factors obtained before randomization. The threshold for ASPECTS corresponds to the median value accord-
ing to the core laboratory evaluation. The measurement of effect size was a cumulative logistic-regression odds 
ratio (shift analysis). Squares indicate point estimates for the treatment effect, and the sizes of the squares are pro-
portional to the precision of the estimate. The odds ratio for intracranial occlusion of the internal carotid artery 
(ICA) cannot be estimated because of a lack of values across the entire range. In patients with intracranial occlu-
sion of the ICA, the difference in the rates of a score of 0 to 2 on the modified Rankin scale between the thrombec-
tomy group and the control group (23.1% vs. 7.7%) was not significant (P = 0.60 by Fisher’s exact test). M1 denotes 
the main trunk of the middle cerebral artery, NIHSS National Institute of Health Stroke Scale, and TICA terminal 
internal carotid artery.
bectomy-associated adverse events. Nonetheless, 
at 90 days, the between-group difference in 
mortality was still not significant. Except for 
complications specific to thrombectomy, all of 
which were infrequent, major adverse event 
were evenly distributed between the two 
groups.
Our study has several limitations. Because of 
ethical considerations, the study was stopped 
before formal stopping boundaries were reached. 
In addition, the SONIIA registry captured only 
patients who were treated with reperfusion 
therapies and did not include all patients who 
were eligible for reperfusion therapies or who 
met the study criteria for eligibility.
In conclusion, our study contributes evidence 
to support the efficacy of neurovascular throm-
bectomy in patients with anterior circulation 
stroke who could be treated within 8 hours after 
the onset of symptoms.
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